Life Sciences News Feeds
Error fetching feed: Retrieved unsupported status code "404"
Error fetching feed: Retrieved unsupported status code "404"
Error fetching feed: Retrieved unsupported status code "404"
Error fetching feed: Retrieved unsupported status code "404"
Error fetching feed: Retrieved unsupported status code "404"
Error fetching feed: Retrieved unsupported status code "404"
Error fetching feed: Retrieved unsupported status code "404"
- Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)14 August 2026, 12:30 pm
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on August 12, 2026, the company granted restricted stock units (RSUs) with respect to 3,315 shares of the company’s common stock to two newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company’s board of directors, and were made as a material inducement t
- Enigma Biomedical USA Announces FDA Approval of TAUKLARIFY™ (florquinitau F 18 injection) for Use in Patients Being Evaluated for Alzheimer’s Disease14 August 2026, 12:15 pm
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Enigma Biomedical USA (EB USA) today announced the U.S. Food and Drug Administration (FDA) approval of TAUKLARIFY™ (florquinitau F 18 injection, also previously referred to as MK-6240), a radiodiagnostic agent indicated for positron emission tomography (PET) of the brain in adults with cognitive impairment who are being evaluated for Alzheimer’s disease to identify patients with tau neurofibrillary tangle (NFT) pathology. In 2023, EB USA sold its subsidiary, C
- Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments14 August 2026, 11:30 am
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced the appointments of Deepak Tiwari as Senior Vice President, Technical Operations, and Matt Biegler as Senior Vice President, Investor Relations, as the company prepares for upcoming PIKTOR clinical milestones. Tiwari will lead Faeth’s technical operations organization, overseeing chemistry, manufacturing and controls (CMC), and supply chain activities supporting the company’s PIKTOR clinical development progr
- Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update14 August 2026, 11:30 am
DALLAS--(BUSINESS WIRE)--Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update
- Bonerge Launches Clinical Trial Investigating Circadian Recovery in Night Shift Healthcare Workers14 August 2026, 7:44 am
NEW YORK--(BUSINESS WIRE)-- #CircadianHealth--Bonerge launches a placebo-controlled trial on StanYouth® Urolithin A, examining how night shift hospital workers recover from circadian disruption.
- Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency14 August 2026, 5:00 am
NEW YORK & LYON, France--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-07307405, the companies’ 6-valent outer surface protein A (OspA)-based Lyme disease vaccine candidate and will begin its assessment of the application. The application is based on encouraging efficacy of more than 70% observed in the Phase 3 VALOR “Vaccine A
- Health Optimization & Longevity Arrives in Boulder: Next Health Celebrates Grand Opening with Live Podcast Recording Featuring Dr. Darshan Shah and Ben Greenfield13 August 2026, 10:00 pm
BOULDER, Colo.--(BUSINESS WIRE)-- #bengreenfield--Next Health celebrates its grand opening in Boulder, Colorado with a live EXTEND Podcast recording featuring Dr. Darshan Shah and Ben Greenfield.
- U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse13 August 2026, 9:12 pm
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CELMoD--U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS
- Simulations Plus Announces Expiration of Hart-Scott-Rodino Waiting Period for Pending Acquisition by Altaris13 August 2026, 9:00 pm
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in connection with the Company's previously announced acquisition by Altaris, LLC. The expiration of the HSR waiting period satisfies one of the regulatory cond
- Sensus Healthcare Reports Second Quarter 2026 Financial Results and Business Highlights13 August 2026, 8:22 pm
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced financial results and business highlights for the three months ended June 30, 2026. Highlights included: Revenues of $2.3 million for the quarter ended June 30, 2026, a decrease of $5.0 million, from the 2025 quarter. The decrease was driven by a lower number of un
- Alpha Cognition Inc. Reports Second Quarter 2026 Financial Results and Provides Operational Update13 August 2026, 8:05 pm
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today reported financial results for the second quarter ended June 30, 2026, and provided a business update. “We are pleased with the continued commercial adoption of ZUNVEYL during the second quarter,” said Michael McFadden, Chief Executive Officer of Alpha
- HealthWarehouse.com Reports Results for Second Quarter 202613 August 2026, 8:05 pm
CINCINNATI--(BUSINESS WIRE)--HealthWarehouse.com Reports Results for Second Quarter as Strategic Partnership Accelerates Integration of AI Across Operations
- Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update13 August 2026, 8:01 pm
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the second quarter ended June 30, 2026, and provided a business update. “We have worked hard to strengthen Gossamer and
- HeartBeam Reports Second Quarter 2026 Results13 August 2026, 8:01 pm
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Reports Second Quarter 2026 Results
- Zoetis Receives Emergency Use Authorization for Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies13 August 2026, 7:51 pm
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. today announced that Simparica Trio has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment of infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies. Larvae of Cochliomyia hominivorax, commonly called New World screwworm (NWS), feed on living tissues, such as open wounds, of animals including livestock, wildlife and pets, and can inflict da
- Saptalis Pharmaceuticals and Coformer AI Partner to Develop Next-Generation Drug Formulations for Neurology and Oncology13 August 2026, 7:13 pm
HAUPPAUGE, N.Y.--(BUSINESS WIRE)--Saptalis Pharmaceuticals and Coformer AI today announced a strategic research partnership to develop next-generation pharmaceutical formulations that address some of the industry's most persistent challenges, including poor solubility, low bioavailability, and dose-limiting toxicity. The collaboration will initially focus on neurology and oncology programs where improved formulation performance may translate into better therapeutic outcomes. The partnership bri
- AIVITA Biomedical Nominated for 2026 Prix Galien USA Award13 August 2026, 7:05 pm
IRVINE, Calif.--(BUSINESS WIRE)--AIVITA Biomedical named a 2026 Prix Galien USA "Best Startup" nominee for its personalized cancer immunotherapy platform.
- Centrum Reframes Healthy Aging as a Proactive Practice for Adults 35 and Beyond13 August 2026, 7:00 pm
WARREN, N.J.--(BUSINESS WIRE)--Centrum, the #1 doctor- and pharmacist-recommended multivitamin brand by Haleon, today announced the launch of Centrum Age Defy, its newest multivitamin line designed for adults ages 35+ looking to proactively support their health as they age. Across generations, adults are taking a more proactive approach to their long-term health, recognizing that everyday choices can shape how they feel for decades to come. With the introduction of Centrum Age Defy alongside th
- Compliance Group Launches AI Agents for Life Sciences to Accelerate Quality Reviews, Strengthen Audit Readiness, and Reduce Validation Time13 August 2026, 6:52 pm
LIBERTYVILLE, Ill.--(BUSINESS WIRE)-- #Audit_Readiness--Compliance Group extends three years of investment in agentic AI for regulated industries with purpose-built agents for life sciences quality, validation, and compliance teams. Compliance Group today announced a portfolio of AI agents: APQR (Annual Product Quality Review), ATR (Audit Trail Review), and VERA (Validation Documentation), powered by CLAiRE, its agentic AI harness platform for regulated industries. The agents are designed to automate critical qua
- Radoff-JEC Group Calls on Seer, Inc.’s Board of Directors to Publicly Acknowledge That the Company Needs to Be Taken Private and Disclose Timeline for Evaluating Latest Acquisition Offers13 August 2026, 5:00 pm
HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff and Michael Torok, who collectively own approximately 7.7% of the outstanding shares of Seer, Inc. (NASDAQ: SEER) (the “Company”), today issued the following open letter to the Company’s Board of Directors. *** August 13, 2026 Seer, Inc. 3800 Bridge Parkway, Suite 102 Redwood City, California 94065 Attn: Board of Directors Dear Members of the Board of Directors (the “Board”), Bradley L. Radoff and Michael Torok (together with certain of their affiliat
- n1.care Launches Clinical Intelligence Platform That Turns Years of Medical Records Into One Clear Clinical Picture13 August 2026, 4:00 pm
DOVER, Del.--(BUSINESS WIRE)-- #ClinicalDecisionSupport--n1.care launches an AI-powered clinical intelligence platform that transforms fragmented medical records into structured clinical insights.
- BTG Pactual TIG and Conservation International Reach 20,000 Hectares of Cerrado Under Restoration, Accelerating Latin American Reforestation Strategy, Increasing Biodiversity and Social Impacts13 August 2026, 3:47 pm
NEW YORK--(BUSINESS WIRE)--BTG Pactual TIG and Conservation International reach 20,000 hectares of Cerrado under restoration, increasing biodiversity and social impacts
- Landmark International Brain Health Initiative Deploys NeuraLight's Biomarkers to Quantify Change in Brain Function13 August 2026, 3:27 pm
NEW YORK & TEL AVIV, Israel--(BUSINESS WIRE)--NeuraLight, a leader in precision brain function biomarkers, today announced that its platform will be deployed as part of the Healthy Brain Ageing (HeBA) study, a landmark European initiative advancing how brain function is measured and tracked across the aging population. The collaboration deploys NeuraLight’s precision brain function biomarkers in a population-scale program built to detect the earliest changes in the brain, up to a decade before
- SurGenTec® Named to the 2026 Inc. 5000 List of America's Fastest-Growing Private Companies13 August 2026, 3:00 pm
BOCA RATON, Fla.--(BUSINESS WIRE)-- #HealthcareInnovation--SurGenTec®, a developer of surgical technologies for spine and orthopedic procedures, today announced that it has been named to the 2026 Inc. 5000, the annual list of the fastest-growing private companies in America. The prestigious list recognizes companies that have achieved remarkable growth while driving innovation, creating jobs, and shaping the future of the economy. Companies on the 2026 Inc. 5000 are ranked according to percentage revenue growth from 2
- PercAssist Announces First Patient Enrolled in AVANXA Clinical Feasibility Study using the eVAD™ System for Biventricular Mechanical Circulatory Support13 August 2026, 2:30 pm
SANTA CLARA, Calif.--(BUSINESS WIRE)--PercAssist, Inc., a medical device company developing innovative technology for extravascular Biventricular Mechanical Circulatory Support to provide hemodynamic improvements for patients in cardiogenic shock (CS), today announced the first patient enrollment for the AVANXA Feasibility Study was successfully conducted in São Paulo, Brazil. “I am thrilled to share the successful clinical use of the PercAssist eVAD System in a patient with SCAI Stage D CS,” s
- Clinilabs Announces Leadership Expansion and Welcomes Laura Shannon as Chief Executive Officer and Promotion of Founder Gary Zammit, Ph.D., to Executive Chairperson13 August 2026, 2:05 pm
EATONTOWN, N.J.--(BUSINESS WIRE)--Clinilabs, a leading specialty contract research organization (CRO) focused on central nervous system (CNS) drug and device development, today announced leadership expansion. Laura Shannon joins the organization as Chief Executive Officer as Gary Zammit, Ph.D., the Company’s founder, assumes the role of Executive Chairperson. This expansion of the senior leadership team is a recognition of a growing organization with global capabilities and continuing commitmen
- RIS Rx Extends Triple A Platform with Real-Time Monitoring Backed by PharmD-to-PharmD Engagement13 August 2026, 2:00 pm
IRVINE, Calif.--(BUSINESS WIRE)-- #GTN--RIS Rx's pharmacy copay misuse product, Triple A, now flags misprocessed claims in real time; PharmD-to-PharmD engagement corrects and recoups funds.
- bioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules13 August 2026, 1:07 pm
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies announces pricing of $4M private placement offering.
- Protolabs Supports MIT Industrial Performance Center Research Fellows to Accelerate U.S. Medical and Aerospace Manufacturing Innovation13 August 2026, 1:00 pm
MINNEAPOLIS--(BUSINESS WIRE)--Protolabs (NYSE: PRLB), the world’s leading provider of digital manufacturing services, today announced a grant to support research fellows at the MIT Industrial Performance Center as they study leading U.S. manufacturing innovators and identify what it takes to scale the nation’s most advanced technologies. The U.S. leads the world in developing breakthrough technologies from new aircrafts to medical technologies, but manufacturers still face significant challenge
- Artera Enrolls First Patient in DIRECT-AI Registry, Marking Milestone in Real-World Evidence Generation for AI-Powered Prostate Cancer Care13 August 2026, 1:00 pm
SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, today announced the enrollment of the first patient in its DIRECT-AI registry study, marking the beginning of real-world prospective evidence generation for the first nationwide registry evaluating the clinical utility of an AI-powered prostate cancer test. The first patient was enrolled at The Urology Place, a leading independent urology practice in S
- PhenoNet Cleared by FDA to Begin Phase 3 Trial of Inhaled PHENOGENE-1A in Early Alzheimer's Disease13 August 2026, 1:00 pm
CAMBRIDGE, Mass.--(BUSINESS WIRE)--FDA clears PhenoNet Inc. to advance PHENOGENE-1A into Phase 3 trials for early Alzheimer’s disease, including APOE4 and non-APOE4 patients.
- Khartis Therapeutics Emerges from Stealth with $95 Million in Funding to Advance Oral Small Molecule Immunology Pipeline13 August 2026, 1:00 pm
SAN DIEGO--(BUSINESS WIRE)--Khartis Therapeutics, a biotechnology company developing both first- and best-in-class oral small molecule medicines for immunological and chronic diseases, announced today that it has raised $50 million in Series B financing. The round was led by Forge Life Science Partners, with participation from Longwood Fund and Alexandria Venture Investments, alongside existing investors Foresite Capital, Lilly Asia Ventures and Nextech Invest, bringing total capital raised to
- Sarah Cannon Research Institute and Merck Collaborate to Expand Access to Oncology Clinical Trials13 August 2026, 1:00 pm
NASHVILLE, Tenn.--(BUSINESS WIRE)--Sarah Cannon Research Institute (SCRI) announced a strategic collaboration with Merck to utilize SCRI’s Accelero™ delivery model.
- HOMELINK® Welcomes Tedd Thomas and Brian Moore to Support Continued National Growth13 August 2026, 1:00 pm
WATERLOO, Iowa--(BUSINESS WIRE)--HOMELINK®, a leading provider of integrated specialty services for the workers’ compensation and group health industries, is pleased to welcome Tedd Thomas as vice president of national sales and Brian Moore as national account executive. Together, they bring extensive experience in sales leadership, managed care, provider relations, and workers’ compensation programs. Thomas brings more than 25 years of experience leading sales teams, driving company growth, an
- Sensus Healthcare Reports Second Quarter 2026 Financial Results and Business Highlights13 August 2026, 8:22 pm
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced financial results and business highlights for the three months ended June 30, 2026. Highlights included: Revenues of $2.3 million for the quarter ended June 30, 2026, a decrease of $5.0 million, from the 2025 quarter. The decrease was driven by a lower number of un
- SurGenTec® Named to the 2026 Inc. 5000 List of America's Fastest-Growing Private Companies13 August 2026, 3:00 pm
BOCA RATON, Fla.--(BUSINESS WIRE)-- #HealthcareInnovation--SurGenTec®, a developer of surgical technologies for spine and orthopedic procedures, today announced that it has been named to the 2026 Inc. 5000, the annual list of the fastest-growing private companies in America. The prestigious list recognizes companies that have achieved remarkable growth while driving innovation, creating jobs, and shaping the future of the economy. Companies on the 2026 Inc. 5000 are ranked according to percentage revenue growth from 2
- DermCare Management and U.S. Dermatology Partners Complete Strategic Transaction to Combine Operations, Creating One of the Largest Dermatology Group Practices in the U.S.13 August 2026, 12:00 pm
HOLLYWOOD, Fla. & DALLAS--(BUSINESS WIRE)--DermCare Management, LLC (“DermCare”), a leader in specialized dermatology and cosmetic surgery practice-management services, and U.S. Dermatology Partners (“USDP”), a leading dermatology practice, today announced the completion of a strategic transaction that creates one of the largest dermatology groups in the U.S., spanning 12 states. The transaction unites two clinically focused organizations with aligned missions to expand access to high-quality d
- Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer12 August 2026, 1:22 pm
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that, on August 12, 2026, its partner Akeso Inc. (Akeso, HKEX Code: 9926.HK) announced receipt of marketing authorization in China from the National Medical Products Administration (NMPA) for the use of ivonescimab, a novel, potential first-in-class investigational bispecific antibody, in combination with chemotherapy for the first-line treatment of patients with advanced squamous non-small cell lung cancer (NSCLC). Thi
- TherapeuticsMD Announces Second Quarter 2026 Financial Results11 August 2026, 8:00 pm
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended June 30, 2026. Second Quarter 2026 Financial Results Net Income from Continuing Operations Net income from continuing operations totaled $164 thousand, compared to net income of $545 thousand for the second quarter of 2025. License Revenues from Continuing Operations The Com
- Belenos Biosciences Announces Positive Topline Results from a Phase 2 Clinical Trial of BEL512 in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)11 August 2026, 3:10 pm
SARASOTA, Fla.--(BUSINESS WIRE)--Belenos Biosciences Announces Positive CRSwNP Results
- ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer11 August 2026, 12:30 pm
WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the appointments of Jim Wassil, currently Chief Operating Officer at Vaxcyte; Suha Jhaveri, former Strategic Advisor at Cidara before its acquisition by Merck; and Bill Warren, former Global Head of Antigen Design at Sanofi Vaccines, as independent members of ILiAD’s Board of Directors. T
- American Ocean Minerals Appoints Paul Warmé as Chief Financial Officer11 August 2026, 12:30 pm
TAMPA, Fla.--(BUSINESS WIRE)--American Ocean Minerals Corporation ("AOMC" or the "Company") today announced that Paul Warmé has been appointed Chief Financial Officer. Through its previously announced merger with Odyssey Marine Exploration (NASDAQ: OMEX), AOMC is establishing a U.S.-based global supply chain for critical minerals and rare earth elements sourced from deep-sea polymetallic nodules, and Warmé’s appointment further strengthens the executive leadership team as the Company advances t
- Leaf Health Integrates PriceMDs’ API into LeafIQ11 August 2026, 12:06 pm
CLEARWATER, Fla.--(BUSINESS WIRE)--PriceMDs and Leaf Health today announced the integration of PriceMDs’ API into LeafIQ, Leaf Health’s pharmacy analytics and reporting platform. The integration enables brokers and third-party administrators to evaluate applicable SourceDirectRx pricing and initiate clinical referrals while analyzing pharmacy spend and specialty medication exposure. Within LeafIQ, users can compare a plan’s current medication cost with available SourceDirectRx pricing without l
- Silvec Announces EPA Registration for its Novel Therapy Delivery Technology10 August 2026, 10:19 pm
GAITHERSBURG, Md.--(BUSINESS WIRE)--Silvec Biologics Inc., a Maryland-based agricultural biotechnology company, is pleased to announce that its novel RNA-based therapy delivery product is now registered for unconditional commercial use under the U.S. Environmental Protection Agency’s (EPA) Federal Insecticide, Fungicide and Rodenticide Act. The product is based on a naturally non-transmitted version of the citrus tristeza virus that is already found in most Florida citrus trees that has been re
- Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results6 August 2026, 8:05 pm
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced business updates and financial results for the second quarter ended June 30, 2026. Recent Business Highlights Cash and cash equivalents totaled $101.6 million as of June 30, 2026. During Q2 the Company raised $46.8 million in net proceeds through an at-the-market (ATM) program, raising approxim
- Redwire’s SpaceMD Announces its First Commercial Mission on SpaceX’s Starfall Spacecraft to Scale In-Space Pharmaceutical Development6 August 2026, 3:00 pm
JACKSONVILLE, Fla.--(BUSINESS WIRE)---- $RDW--Space Microgravity Development LLC (SpaceMD), a wholly owned subsidiary of Redwire Corporation (NYSE:RDW) and venture company focused on leveraging the microgravity environment to create dynamic innovations, announced today that it has signed a contract for a Starfall mission. Starfall is SpaceX’s new spacecraft that enables affordable, routine access to a microgravity environment and provides unique opportunities for on-orbit manufacturing, scientific resea
- Rose Rock Bridge Winners Will Pilot New Technologies with Energy Leaders6 August 2026, 2:00 pm
TULSA, Okla.--(BUSINESS WIRE)--Four startups headquartered in Colorado, Florida and Texas have been selected as winners of the 2026 Rose Rock Bridge Showcase. Austere Environmental, BiaTech, BigMachine AI and Intellicess will receive a share of $400,000 in non-dilutive funding and establish a presence in Tulsa to pilot and advance their technologies over the next year. The winning startups were selected from a pool of 85 highly qualified applicants. Collectively, they have already raised over $
- OneOncology and OpenEvidence Partner to Improve Cancer Care Nationwide6 August 2026, 1:00 pm
MIAMI & NASHVILLE, Tenn.--(BUSINESS WIRE)-- #Oncology--OpenEvidence, the most widely used AI-powered medical search and clinical decision-support platform, and OneOncology, a physician-led national platform empowering independent medical specialty practices, today announced a partnership to embed OpenEvidence into certain clinical applications used across OneOncology’s platform to enable physicians to use OpenEvidence for clinical evidence retrieval, reference and research. The integration is designed to m
- Springer Nature and OpenEvidence Announce Agreement to Maximise Exposure of Trusted Findings On OpenEvidence Platform5 August 2026, 12:00 pm
NEW YORK & MIAMI--(BUSINESS WIRE)-- #OpenEvidence--Springer Nature and OpenEvidence today announced a subscription agreement that brings peer-reviewed content from Springer Nature into OpenEvidence, where physicians can retrieve and cite it during patient care. This agreement took effect August 4 and forms part of Springer Nature’s community led ARC3 framework. Clinicians and healthcare professionals need quick and easy access to the very latest trusted insights to help inform their decisions. Today's announce
- Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer5 August 2026, 11:00 am
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the expansion of its global registration-enabling clinical development program for the novel, potential first-in-class investigational bispecific antibody ivonescimab, into urothelial carcinoma, or bladder cancer, with the initiation of the global, multi-regional Phase II/III HARMONi-GU1 trial. Summit is starting a randomized Phase II/III clinical study, HARMONi-GU1, to evaluate ivonescimab plus the antibody-drug co
- Publix Reports Second Quarter 2026 Results and Stock Price3 August 2026, 2:59 pm
LAKELAND, Fla.--(BUSINESS WIRE)--Publix’s sales for the three months ended June 27, 2026 were $15.7 billion, a 1% increase from $15.6 billion in 2025. Publix’s sales for the six months ended June 27, 2026 were $31.9 billion, a 1.5% increase from $31.4 billion in 2025. The increase in sales for the three and six months ended June 27, 2026 compared to the three and six months ended June 28, 2025 was lower due to the impact of the Medicare maximum fair price (MFP) change effective January 1, 2026
- Family Heart Foundation Founder and CEO Katherine Wilemon Named Honorary Fellow Awardee by the American Society for Preventive Cardiology3 August 2026, 12:00 pm
FERNANDINA BEACH, Fla.--(BUSINESS WIRE)-- #ASPC2026--The Family Heart Foundation, a leading research, education and advocacy organization, today announced that Founder and Chief Executive Officer Katherine Wilemon has been named the 2026 Honorary Fellow Awardee by the American Society for Preventive Cardiology (ASPC), one of the nation's leading professional societies dedicated to advancing cardiovascular disease prevention. The award was presented during the ASPC 2026 Congress on Cardiovascular Disease Pre
- Sensus Healthcare to Report Second Quarter 2026 Financial Results and Hold Business Update Conference Call on August 13, 202630 July 2026, 8:05 pm
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced the company will report financial results for the second quarter of 2026 on Thursday, August 13, 2026. Management will hold a conference call beginning at 4:30 pm Eastern time to review the results, provide a business update and answer questions.Participants are enc
- EnlivenHealth Highlights VaxReach Ahead of ThoughtSpot 2026 — Designed to Help Pharmacies Strengthen Communities Through Vaccination30 July 2026, 8:01 pm
FORT WORTH, Texas--(BUSINESS WIRE)--EnlivenHealth Highlights VaxReach Ahead of ThoughtSpot 2026 — Designed to Help Pharmacies Strengthen Communities Through Vaccination
- PVP Labs Selected to Present Taphalgin® (Lumekefamide) as a Novel Battlefield Pain Solution at 2026 MHSRS30 July 2026, 4:10 pm
KISSIMMEE, Fla.--(BUSINESS WIRE)-- #BattlefieldMedicine--PVP Labs, a clinical-stage biotechnology company advancing peptide-based therapeutics, today announced that research on Taphalgin® (Lumekefamide) has been selected for oral presentation at the 2026 Military Health System Research Symposium (MHSRS), a premier scientific forum focused on the unique medical needs of deployed Warfighters.Joseph Stauffer, D.O., MBA, FAPCR, Chief Medical Officer of PVP Labs, will present the company's research on Taphalgin as a promis
- Jackson PharmacyPros Named to RXinsider’s 2026 Pharmacy500 List30 July 2026, 1:00 pm
ORLANDO, Fla.--(BUSINESS WIRE)--Jackson PharmacyPros™, a pharmacy-exclusive staffing agency and workforce solutions provider, has been named to RXinsider's 2026 Pharmacy500, an annual recognition honoring the top pharmacy operations, supply chain businesses and associations that have made a significant impact on dispensing pharmacies across the United States over the past year. The 2026 listmakers are shaping the future of pharmacy through operational excellence, innovation and exceptional pati
- Publix Pharmacy Participates in the Medicare GLP-1 Bridge Program30 July 2026, 1:00 pm
LAKELAND, Fla.--(BUSINESS WIRE)--Eligible Medicare Plan D beneficiaries can have qualifying GLP-1 prescriptions filled at a Publix Pharmacy as part of the Medicare GLP-1 Bridge program. On July 1, 2026, the Centers for Medicare & Medicaid Services launched the Medicare GLP-1 Bridge program, a new initiative designed to expand access to innovative GLP-1 drugs for weight management. The program will remain available through Dec. 31, 2027. Covered Prescriptions The GLP-1 drugs currently availa
- CONMED Corporation Reports Second Quarter 2026 Financial Results; Updates Full Year 2026 Guidance29 July 2026, 8:05 pm
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today reported financial results for the second quarter ended June 30, 2026 and updated its financial guidance for the full year ending 2026. Second Quarter 2026 Highlights(1) Sales of $343.5 million increased 0.3% year-over-year as reported and decreased 0.5% on a constant currency(2) basis. Excluding the impact of the Company’s previously announced strategic exits of GI product offerings, net sales increased 6.0% on an organic cons
- Massive Bio and QC Healthcare Announce National Collaboration to Transform Cancer Patient Access29 July 2026, 2:00 pm
BOCA RATON, Fla. & CHARLOTTE, N.C. & ATLANTA--(BUSINESS WIRE)--Massive Bio, Inc., a leader in AI-enabled oncology clinical trial matching and patient navigation, and QC Healthcare, LLC, a nationwide company focused on telehealth, clinical research, pharmacy services, artificial intelligence, healthcare analytics, and population health, today announced a strategic collaboration to fundamentally reshape how cancer patients access clinical trials, coordinated care, and telehealth support throughou
- NeoGenomics Reports Second Quarter 2026 Results28 July 2026, 8:05 pm
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its second-quarter results for the period ended June 30, 2026.
- Florida Schools Invited to Participate in Math Study from UF Lastinger Center and Kiddom28 July 2026, 1:30 pm
GAINESVILLE, Fla.--(BUSINESS WIRE)--Kiddom and the University of Florida Lastinger Center announced a research partnership studying if and how embedding professional learning at a teacher's precise point-of-need impacts instruction and student outcomes in middle school math.Kiddom built Florida's B.E.S.T.-aligned math curriculum to give teachers their core instructional materials, assessments, and insights in one coherent system. This partnership goes further, weaving Lastinger Center's instruct
- Greenspace Health Launches ‘Momentum’ to Help Advance the Future of Measurement-Based Care28 July 2026, 12:46 pm
ST. AUGUSTINE, Fla.--(BUSINESS WIRE)-- #MBC--Greenspace Health, a leader in Measurement-Based Care (MBC) technology for behavioral health, has launched Momentum, a new industry publication created to help behavioral health leaders navigate the growing shift toward outcomes-focused, value-based care. Featuring research, real-world case studies and practical implementation strategies, Momentum provides evidence-informed insights into the clinical, operational and economic impact of Measurement-Based Car
- Massive Bio and GELL Announce Strategic Partnership to Advance Research, Medical Education, and Artificial Intelligence Across Latin America and the United States27 July 2026, 2:00 pm
BOCA RATON, Fla.--(BUSINESS WIRE)--Massive Bio, a global leader in artificial intelligence-driven solutions for oncology, clinical trial matching, and patient navigation, and the Latin American Study Group on Lymphoproliferative Disorders (GELL), one of the most influential scientific and academic networks dedicated to lymphomas and hematologic malignancies in Latin America, today announced a strategic partnership focused on advancing clinical research, physician education, and innovation throu
- Sugar Sands Publishing LLC Announced Publication of a Highly Anticipated AI Safety Standards Suite27 July 2026, 11:00 am
PENSACOLA, Fla.--(BUSINESS WIRE)--Sugar Sands Publishing LLC today announced the formal constitution of the independent Cognitive Mode Operating System Standards Board (CMOS-SB) and launch of a governance framework for how AI systems interact with human emotion and cognition. THE GOVERNANCE GAP AI systems are increasingly being used in enterprise, health care, education and public infrastructure, where they can read emotional cues, respond to cognitive patterns and influence how people relate t
- SurGenTec® Secures FDA Clearance for ION-L™ - Lumbar Navigation Compatible24 July 2026, 3:10 pm
BOCA RATON, Fla.--(BUSINESS WIRE)-- #FDAClearance--SurGenTec®, a medical device company focused on advancing treatment options for orthopedic and spine surgery, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its ION-L™ navigation instruments for use with the ION-L™ Lumbar Facet Fixation System. The system is engineered for compatibility with Medtronic's StealthStation™ navigation platform, enabling enhanced precision during posterior lumbar facet fusion proced
- Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 202623 July 2026, 8:05 pm
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today reported its financial results for the second quarter and six months ended June 30, 2026 and provided an update on clinical and operational progress. “The clinical momentum of ivonescimab continues to build, with two recent key data readouts that significantly bolster our development progress. At ASCO, the landmark HARMONi-6 results established the first head-to-head Phase III study in any tumor type to demonstrate a meaningf
- Thyora Therapeutics Launches to Build a Next-Generation Platform for Covalent Drug Discovery23 July 2026, 6:00 pm
TAMPA, Fla.--(BUSINESS WIRE)-- #biotech--Thyora Therapeutics today emerged from stealth as a biotechnology company leveraging next-generation covalent chemistry, with a mission to accelerate clinical translation and create therapies for high-unmet medical needs. Founded on breakthrough discoveries published today in Science by scientists at Moffitt Cancer Center, the company is advancing an integrated platform that combines novel covalent chemistry with AI-enabled chemoproteomics to unlock a new generatio
- Los Angeles County Department of Public Health and OpenEvidence Partner to Connect Physicians With Local Public Health Guidance23 July 2026, 1:00 pm
MIAMI & LOS ANGELES--(BUSINESS WIRE)-- #ClinicalAI--The Los Angeles County Department of Public Health (DPH) and OpenEvidence, an AI-powered clinical decision support platform, today announced a collaboration to help physicians quickly find official LA County Public Health resources when searching for clinical information. Under this new partnership, when physicians in LA County search the platform for selected public health topics, OpenEvidence will display related LA-specific messages from Public Health. T
- Avanti Capital Expands Philanthropic Mission as The Foundation Establishes U.S. Presence23 July 2026, 4:00 am
BOCA GRANDE, Fla.--(BUSINESS WIRE)--Avanti Capital establishes The Foundation in the U.S., advancing a multigenerational philanthropic legacy focused on research, education and impact.
- Arcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer22 July 2026, 8:30 pm
HAYWARD, Calif. & MIAMI--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, and Summit Therapeutics Inc. (Nasdaq: SMMT), a biopharmaceutical company focused on patient-friendly oncology therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical ne
- Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer22 July 2026, 8:30 pm
HAYWARD, Calif. & MIAMI--(BUSINESS WIRE)---- $SMMT--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, and Summit Therapeutics Inc. (Nasdaq: SMMT), a biopharmaceutical company focused on patient-friendly oncology therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical ne
- ReturnPro Releases “The GLP-1 Effect” Report Showing Significant Changes in GLP-1 Users’ Shopping Patterns and Returns Behaviors22 July 2026, 1:01 pm
MIAMI--(BUSINESS WIRE)--ReturnPro, the industry leader in returns management and reverse logistics, today announced findings from its new consumer study examining the effects of GLP-1 medications and how they are quietly reshaping what consumers are buying, returning, holding onto and wishing retailers would do differently to address their unique needs. The GLP-1 Effect report surveyed 500 U.S. adults currently taking, or who have taken within the past 12 months, a GLP-1 medication (Ozempic, We
- Cancer Cell Diagnostics (CCDx) Debuts Whole-Cell Genomic Profiling to Redefine Liquid Biopsy22 July 2026, 1:00 pm
JUPITER, Fla.--(BUSINESS WIRE)--Cancer Cell Diagnostics today announced the commercial launch of its CellSight™ DNA comprehensive genomic profiling test. This test is built on a fundamentally distinct source material from conventional liquid biopsy. Most blood-based cancer tests analyze cell-free circulating tumor DNA, the short, degraded fragments that tumors shed into the bloodstream. CCDx utilizes a different approach. The CellSight™ platform uses a proprietary, patent-pending enrichment met
- CONMED Corporation Announces Expanded Indication for the FDA Cleared AirSeal® Robotic Solution for Use with the Intuitive da Vinci 5 Hex Cannula22 July 2026, 11:00 am
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that its AirSeal® Robotic Solution is now indicated for use with Intuitive’s 8 mm hex cannulas used as part of the Intuitive da Vinci 5 platform (“dV5”). Alongside its existing indication for Intuitive 8 mm round cannulas, the AirSeal Robotic Solution now has an expanded indication for use across Intuitive’s portfolio of da Vinci X, da Vinci Xi, and da Vinci 5 robotic systems. Building on the existing indication for I
- Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study22 July 2026, 10:30 am
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (Nasdaq: SMMT) today announced results of an updated overall survival (OS) analysis from the global Phase III HARMONi clinical trial featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab. Ivonescimab plus platinum-doublet chemotherapy in this trial continues to show a positive OS trend and a consistent efficacy and safety profile in Asian and western patients when compared to chemotherapy alone. The HARMONi
- Vasomune Therapeutics to Present on Vascular Leak in Combat-Relevant Injury at the 2026 Military Health System Research Symposium21 July 2026, 11:45 pm
TORONTO--(BUSINESS WIRE)-- #ARDS--Dr. Harold Kim, Chief Scientific Officer, will present at the 2026 Military Health System Research Symposium (MHSRS), DOW's premier scientific meeting
- Redwire Opens State-of-the-Art Facility in Indiana to Accelerate Space-Enabled R&D and Manufacturing with a Focus on Next-Gen Drug Development and Human Health Breakthroughs21 July 2026, 11:00 am
JACKSONVILLE, Fla.--(BUSINESS WIRE)---- $RDW--Redwire Corporation (NYSE: RDW), a global leader in space and defense technology solutions, has opened its new 30,000 square foot state-of-the-art, vertically-integrated research and microgravity payload development facility in Georgetown, Indiana. The facility will serve as a global hub supporting accelerated demand as the company continues to expand its leadership in space-enabled research, development, and manufacturing with a focus on pharmaceutical/biot
- NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS20 July 2026, 9:23 pm
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS
- Massive Bio Partners With FOMAT to Expand Cancer Patient Prescreening for Clinical Trial Access20 July 2026, 4:00 pm
BOCA RATON, Fla.--(BUSINESS WIRE)--Massive Bio partners with FOMAT, the largest U.S. Embedded Research Organization, to launch AI-powered cancer patient prescreening for clinical trials
- Kalogon Launches Verro, a New Medicare-coded Custom Wheelchair Cushion Built for the Most Complex Support Needs20 July 2026, 2:00 pm
MELBOURNE, Fla.--(BUSINESS WIRE)--Kalogon expands its seating line with Verro, a Medicare-coded custom cushion engineered for wheelchair users with complex postural needs.
- Precision IO Group to Present Epione® Robotic Platform and Remote Intervention Program at Society of Robotic Surgery Annual Meeting20 July 2026, 12:50 pm
MIAMI--(BUSINESS WIRE)--Precision IO Group, the parent company of NeuWave Medical and Quantum Surgical, will present at the Society of Robotic Surgery (SRS) Annual Meeting in Hollywood, Florida, July 22–26, 2026, on booth #325. At the meeting, interventional radiology leaders Prof. Dr. Sean Tutton, MD, Professor of Radiology and Orthopedics, and Dr. Govindarajan Narayanan, MD, FSIR, Professor of Radiology and Chief of Interventional Oncology and the first physician to treat a patient with Epion
- CONMED Corporation to Participate in the Society of Robotic Surgery Annual Meeting20 July 2026, 11:00 am
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced its participation in the Society of Robotic Surgery (SRS) 2026 Annual Meeting, which is being held July 23-26, 2026 in Fort Lauderdale, FL. During the meeting, Professor Nikhil Vasdev, FRCS (Urol), MCh (Urol), DSc will present data from a prospective randomized controlled clinical trial conducted by Vasdev et al., which investigated differences in the levels of intraoperative and post-operative pain between two abdomi
- Sun Nuclear to Showcase Next-Generation Innovations at AAPM & COMP 2026 Annual Meeting17 July 2026, 12:30 pm
MELBOURNE, Fla.--(BUSINESS WIRE)--Sun Nuclear, a Mirion Medical company, announced today the featured innovations in quality assurance (QA) for machine oversight and adaptive radiotherapy, as well as AI-assisted treatment planning, to be shown at the 2026 AAPM & COMP Annual Meeting, July 19–21 in Vancouver. Centered on the theme of Next-Gen Innovations for Next-Level Physics, the Sun Nuclear exhibit reflects a focus on smart, practical tools that support medical physics teams to operate wit
- Boston Children’s Hospital and OpenEvidence Collaborate to Advance AI-Powered Analysis of Clinical Practice Patterns16 July 2026, 1:00 pm
MIAMI & BOSTON--(BUSINESS WIRE)-- #medicalAI--Boston Children's Hospital, one of the nation's top pediatric hospitals, and OpenEvidence, the leading AI-powered clinical decision support platform, today announced a multi-year collaboration to examine how clinicians' real-world use of AI tools at the point of care relates to practice patterns and delivery of care. OpenEvidence has seen broad adoption in clinical settings, yet little is known about how that adoption relates to clinical practice patterns at a p
- Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 202616 July 2026, 12:00 pm
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (Nasdaq: SMMT) will host a conference call to announce its second quarter 2026 financial results and provide an update on operational progress on Thursday, July 23, 2026. The call is scheduled to take place at 4:30 p.m. EDT. The live and archived webcast can be accessed through the Investor Information section of the company’s website, www.smmttx.com. About Summit Therapeutics Inc. Summit Therapeutics Inc. is a biopharmaceutical oncology company
- Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2026 Financial Results15 July 2026, 8:30 pm
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2026. Financial Results Revenue The revenues for the second quarter of fiscal 2026 were $7.8 million compared to $7.9 million for the second quarter of fiscal 2025, a 2% decrease. The revenues for the second quarter of fiscal 2026 consisted of $7.7
- Paley Institute Advances the Future of Stature Surgery with Next-Generation Internal Lengthening Technology15 July 2026, 10:00 am
WEST PALM BEACH, Fla.--(BUSINESS WIRE)--The Paley Orthopedic & Spine Institute (Paley Institute), the world's leading center for stature surgery, achieves another historic milestone with the first completed stature surgery utilizing the latest FDA-approved PRECICE Max (PMAX) nail. As the exclusive global launch center for the technology, Paley Institute continues to lead the evolution of modern stature surgery – an advanced application of limb lengthening science pioneered over decades of o
- American Ocean Minerals Highlights Moana Minerals AUV Survey Capturing More Than 600,000 Seafloor Images in the Cook Islands14 July 2026, 12:30 pm
TAMPA, Fla. & RAROTONGA, Cook Islands--(BUSINESS WIRE)--American Ocean Minerals Corporation ("AOMC"), which is building a responsible supply of critical minerals and rare earth elements through its previously announced merger with Odyssey Marine Exploration (NASDAQ: OMEX), today highlighted Moana Minerals Ltd.'s ("Moana Minerals" or "MML") completion of a high-definition autonomous underwater vehicle seafloor survey within its Exploration License 3 (“EL3”) area in the Cook Islands Exclusive Eco
- Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc.14 July 2026, 11:00 am
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced it has signed an agreement with Toronto-based Biossil, Inc. for the sale of ridinilazole, an investigational Phase III precision antibiotic owned by Summit. Biossil is an artificial intelligence (AI)-native biopharma company focused on advancing late-stage programs in life-threatening indications with urgent unmet medical needs. Previously, ridinilazole was evaluated in Summit’s Phase III Ri-CoDIFy study for the tre
- Massive Bio Announces Partnership with Sequence Me Now to Help Cancer Patients Access Clinical Trials13 July 2026, 2:00 pm
BOCA RATON, Fla.--(BUSINESS WIRE)--Massive Bio, a technology company that uses artificial intelligence to help cancer patients identify clinical trials for which they may be eligible, today announced a new partnership with Sequence Me Now (SMN), a nonprofit patient advocacy organization dedicated to helping cancer patients access genomic sequencing and personalized medicine. Through the partnership, Massive Bio is featured on the "Find a Trial" page of Sequence Me Now's website, the fourth step
- OpenEvidence and NewYork-Presbyterian, Columbia University and Weill Cornell Medicine Expand Clinical AI Tools Across New York City and Westchester9 July 2026, 3:00 pm
MIAMI & NEW YORK--(BUSINESS WIRE)-- #MedicalAI--OpenEvidence, a medical AI and clinical decision support tool for U.S. clinicians, today announced a collaboration with NewYork-Presbyterian and its affiliated medical schools, Columbia University Vagelos College of Physicians and Surgeons and Weill Cornell Medicine, to deploy OpenEvidence across all hospitals and care sites throughout the Greater New York region. This enterprise-scale collaboration will place trusted, evidence-based clinical AI in the hands o
- NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer9 July 2026, 11:05 am
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics launched PTEN IHC CDx, the first IHC companion diagnostic test approved by the U.S. FDA for patients with prostate adenocarcinoma.
- OpenEvidence, Anticoagulation Forum Partner to Expand Access to AI-Enabled Guidance in Antithrombotic Care8 July 2026, 4:00 pm
MIAMI & BOSTON--(BUSINESS WIRE)--OpenEvidence and the Anticoagulation Forum (AC Forum) today announced a strategic partnership to provide antithrombotic guidance and tools that support decision-making in clinical practice. By combining the AC Forum’s leadership in education and multidisciplinary clinical guidance with OpenEvidence’s advanced artificial intelligence platform, clinicians will gain access to timely and practical evidence in antithrombotic therapy. “Clinicians are increasingly turn
- Former Merck and NASA Leaders Bring Strategic Expertise to SpaceMD Amid Rising Demand for its In-Space Pharmaceutical Development Capabilities8 July 2026, 11:00 am
JACKSONVILLE, Fla.--(BUSINESS WIRE)--Redwire Corporation (NYSE: RDW), a global leader in aerospace and defense technology solutions, announced today it has appointed pioneering industry leaders Paul Reichert, former Principal Investigator at Merck Research Laboratories, and Niki Werkheiser, former Director of Technology Maturation at NASA’s Space Technology Mission Directorate, to serve in strategic advisory roles at Space Microgravity Development LLC (SpaceMD), Redwire’s venture company focuse
- Pangea Pharmaceuticals Advances Its Next Phase of Growth With an Expanding Commercial Portfolio7 July 2026, 2:13 pm
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Pangea Pharmaceuticals, a U.S.-based, patient-centered pharmaceutical company focused on bringing differentiated, clinically relevant products to market, today announced the next phase of its growth strategy, marked by an expanding portfolio of therapies, growing commercialization capabilities, and continued investment in its pharmaceutical platform. The milestone reflects Pangea's evolution into a scalable pharmaceutical organization focused on identifyi
- Catalent and Nanoscope Therapeutics Expand Partnership to Support Late-Phase Development and Commercial Supply of MCO-0107 July 2026, 1:00 pm
TAMPA, Fla. & DALLAS--(BUSINESS WIRE)--Catalent & Nanoscope Therapeutics Expand Partnership to Support Late-Phase Development and Commercial Supply of Lead Optogenetic Gene Therapy, MCO-010
- DemeRx Strengthens Leadership Team With Appointment of Biopharmaceutical Executive Michael Snitkovsky as Chief Operations Officer7 July 2026, 11:45 am
MIAMI--(BUSINESS WIRE)--DemeRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming addiction therapeutics, today announced the appointment of Michael Snitkovsky as chief operations officer, adding a seasoned biopharmaceutical executive with more than 20 years of experience advancing therapies from preclinical research through clinical development. Mr. Snitkovsky is recognized for his strategic leadership, operational rigor, and ability to unite cross‑functional and globa
- NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 20267 July 2026, 11:05 am
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its second quarter 2026 financial results after the close of U.S. financial markets on Tuesday, July 28, 2026.
- Coral Connect Acquires AdvisorWoRx, Names Founder Edie Gigot President of Infusion Services6 July 2026, 11:19 pm
CORAL SPRINGS, Fla.--(BUSINESS WIRE)--Coral Connect, LLC announced it has acquired AdvisorWoRx, LLC, the strategic healthcare consulting firm founded and led by Edie Gigot, MSN-RN, MBA. Coral is a specialty infusion enablement platform that helps healthcare operators improve their purchasing decisions, operate leaner, and get reimbursed more across every site of care. Gigot joins Coral's executive leadership team as President of Infusion Services, leading the company's clinical operations, phar
- OSSIO Raises the Bar for Sports Medicine at Specialty’s Major Meeting6 July 2026, 1:15 pm
TAMPA, Fla.--(BUSINESS WIRE)-- #AOSSM--OSSIO Inc., a fast-growing medical technology platform company focused on advancing orthopedic surgery with bio-integrative, metal-free fixation implants, today confirmed its slate of activities and announcements planned for the upcoming American Orthopaedic Society for Sports Medicine (AOSSM) 2026 annual meeting at the Seattle Convention Center July 8–11. Update on study of KneeBar Procedure. Interim results from the multicenter, 50-patient clinical study of the c
- CONMED Corporation to Report Second Quarter 2026 Financial Results on July 29, 20262 July 2026, 8:05 pm
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the second quarter 2026 after the market close on Wednesday, July 29, 2026. The Company’s management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed fro
- MuseCell Innovations Enters U.S. Market, Bringing Restorative Stem Cell Therapy Directly to American Patients1 July 2026, 1:00 pm
SINGAPORE--(BUSINESS WIRE)--MuseCell Innovations launches world's only clinically validated stem cell platform in the US for disease treatment, performance, and aesthetics.
- Men’s Health Month: Putting Sexual Wellness in the Spotlight30 June 2026, 1:30 pm
MIAMI--(BUSINESS WIRE)--Men’s Health Month serves as an important reminder that sexual wellness is a fundamental component of overall well-being, yet it is often overlooked in conversations about men’s health. While discussions frequently focus on fitness, mental health, and preventive care, sexual health plays an equally vital role in a man’s quality of life, confidence, and relationships. Prioritizing protection is an important part of maintaining sexual wellness, empowering men to take an ac
- Humata Health Expands Reach of Prior Authorization Technology to Independent Practices, Regional Health Centers and Specialty Clinics30 June 2026, 1:00 pm
WINTER PARK, Fla.--(BUSINESS WIRE)--Humata Health, the leader in AI-powered medical review technology, today announced a new standalone prior authorization platform built for independent practices, regional health centers and specialty clinics. The denial reduction tool analyzes clinical documentation against applicable payer policies before submission and returns a real-time score, identifying gaps in the record that may trigger a denial while reducing time spent on preparation. It also featur
- AHF: Florida Budget Becomes Law, Securing Reversal of HIV Drug Cuts29 June 2026, 6:53 pm
TALLAHASSEE, Fla.--(BUSINESS WIRE)-- #AHFcares--AHF: Florida Budget Becomes Law, Securing Reversal of HIV Drug Cuts
- OpenEvidence and Journal of Medical Insight (JOMI) Partner to Bring Peer-Reviewed Surgical Videos to Clinicians25 June 2026, 4:00 pm
MIAMI & BOSTON--(BUSINESS WIRE)--The Journal of Medical Insight’s peer-reviewed surgical video library is now part of OpenEvidence.
- ReliaQuest Invests $1.5 Million to Advance AI and Cybersecurity Education at the University of South Florida25 June 2026, 1:30 pm
TAMPA, Fla.--(BUSINESS WIRE)--ReliaQuest today announced a $1.5 million investment to expand AI cybersecurity research and education at the University of South Florida’s College of Artificial Intelligence, Cybersecurity and Computing. The gift will establish the college’s first-ever endowed professorship and create a new study track within the ReliaQuest Labs program focused on artificial intelligence-supported software engineering. “Cybersecurity is the greatest technical challenge of our gene
- NeoGenomics Appoints Carolyn Starrett to its Board of Directors25 June 2026, 11:05 am
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the appointment of Carolyn Starrett to its Board of Directors.
- OSSIO Inc.’s Distribution Deal With OrthoPediatrics Corp. Brings Bio-Integrative, Metal-Free OSSIOfiber® Implants to U.S. Children’s Hospitals Nationwide24 June 2026, 4:00 pm
TAMPA, Fla.--(BUSINESS WIRE)-- #medicaldevice--In striking an exclusive distribution agreement with OrthoPediatrics Corp. announced today, OSSIO Inc. expands access to its revolutionary orthopedic fixation technology — bio-integrative, metal-free OSSIOfiber® implants — to the approximately 400 U.S. children’s hospitals and care facilities whose orthopedic surgeons treat most pediatric patients admitted with bone fractures and skeletal deformities. "It’s not often that kids need implants for broken bones, since
- American Ocean Minerals Announces Successful Completion of MV Anuanua Moana Expedition 7, Advancing Deep-Sea Environmental Baseline Research in the Cook Islands24 June 2026, 1:00 pm
TAMPA, Fla.--(BUSINESS WIRE)--Today, American Ocean Minerals Corporation (AOMC) announced the successful completion of Expedition 7, a research campaign designed to support the environmental baseline studies required for future deep-sea mineral exploration and development activities in the Cook Islands. Expedition 7 was conducted over approximately three weeks aboard the MV Anuanua Moana, a proprietary research vessel advancing critical deep-sea environmental and exploration programs across its
- ModMed Scribe 2.0 Surpasses One Million AI-Powered Patient Visits24 June 2026, 12:00 pm
BOCA RATON, Fla.--(BUSINESS WIRE)--ModMed®, a leading provider of software and services to specialty medical practices, today announced that its AI-powered clinical documentation solution, ModMed Scribe 2.0, has been used in more than 1,000,000 patient visits. The explosive growth was driven by a 300% growth rate in usage that climbed from 240,000 visits in March to over 1 million just three months later. ModMed Scribe delivers immediate and dramatic results for clinicians across the specialtie
- SNO and OpenEvidence Launch Official Generative AI Partnership23 June 2026, 4:00 pm
MIAMI & HOUSTON--(BUSINESS WIRE)--The Society for Neuro-Oncology (SNO), the world's largest multidisciplinary organization dedicated to advancing research, education, and clinical care for patients with brain and spinal cord tumors, and OpenEvidence, the leading AI-powered clinical decision support platform, today announced a landmark partnership, designating OpenEvidence as SNO's official generative AI partner. As part of the collaboration, SNO will embed OpenEvidence across its member-facing
- Akumin and CGS Premier Launch Mobile Healthcare Innovations to Scale Akumin AXIS® Portfolio of Relocatable Clinics23 June 2026, 2:00 pm
TAMPA, Fla.--(BUSINESS WIRE)-- #Akumin--Akumin Inc. (“Akumin” or the “Company”), a leading provider of diagnostic imaging and oncology solutions, has announced the formation of Mobile Healthcare Innovations (MHI), a joint venture partnership with Wisconsin based manufacturer CGS Premier, to engineer, assemble and deploy Akumin AXIS® relocatable clinics to meet growing U.S. demand. Leaders cut the ribbon on a new 85,400-square-foot facility in New Berlin, Wisconsin, purposefully built in size and structur
- NationsBenefits Redefines Access Through National Expansion of Integrated Wellness, OTC, and Nutrition Benefits23 June 2026, 11:00 am
PLANTATION, Fla.--(BUSINESS WIRE)-- #NationsBenefits--Eligible health plan members can now use the NationsBenefits® Flex Card at Sam’s Club to simplify grocery, OTC, and health and wellness purchases.
- The Cataltheia Group and Bruno Vision Care Announce Publication of Landmark Clinical Study Validating Deseyne® Extended Depth of Focus Technology for Presbyopia22 June 2026, 12:07 pm
BOCA RATON, Fla.--(BUSINESS WIRE)-- #ClinicalResearch--New study in Optometry and Vision Science validates Bruno Vision Care's Deseyne® EDOF lens technology, expanding options for presbyopia correction.
- Scholar Rock to Showcase Neuromuscular Research Portfolio at 2026 Annual Cure SMA Research and Clinical Care Meeting and 2026 International Research Congress on FSHD22 June 2026, 12:00 pm
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its world-leading platform in myostatin biology, announced today that it will present new clinical data and research updates at Cure SMA’s Annual SMA Research & Clinical Care Meeting being held June 24-26, 2026, in Orlando,
- CONMED Corporation Appoints John E. Gallagher as Chief Financial Officer17 June 2026, 8:35 pm
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced the appointment of John E. Gallagher as Chief Financial Officer (“CFO”), effective July 15, 2026. Mr. Gallagher succeeds Todd Garner, who remains with the Company in an advisory capacity through November 2, 2026. “We are pleased to welcome a talented and experienced financial executive of John’s caliber to CONMED,” said Patrick J. Beyer, CONMED’s President and Chief Executive Officer. “John brings deep healthcare and
- NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes17 June 2026, 10:00 am
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes
- AHF Welcomes Lula–Tedros Call for Equity in Pandemic Agreement, Warns against Rushing Empty Deal16 June 2026, 2:37 pm
MIAMI, GENEVA & SÃO PAULO--(BUSINESS WIRE)-- #Brazil--The AIDS Healthcare Foundation (AHF) and the AHF Global Public Health Institute welcome the open letter issued by President Luiz Inácio Lula da Silva of Brazil and World Health Organization Director-General Dr. Tedros Adhanom Ghebreyesus on the occasion of the G7 Summit, calling on the leaders of the G7, G20, BRICS, and all nations to finish the Pathogen Access and Benefit-Sharing (PABS) annex of the WHO Pandemic Agreement. AHF particularly commends t
- Humanetics Corporation Selected for Oral Presentation at 2026 Military Health System Research Symposium16 June 2026, 1:05 pm
MINNEAPOLIS--(BUSINESS WIRE)--HUMANETICS CORPORATION SELECTED FOR ORAL PRESENTATION AT 2026 MILITARY HEALTH SYSTEM RESEARCH SYMPOSIUM
- LaVoie’s LHS Fifteen-Slide Presentation® for 2026: Make Your Science Stick in the AI Era Returns to BIO 202616 June 2026, 12:37 pm
BOSTON & FORT LAUDERDALE, Fla.--(BUSINESS WIRE)-- #BIO2026--The LHS Fifteen-Slide Presentation® returns to BIO 2026 with new AI-era strategies for building investor-ready biotech stories.
- TriLink Opens GMP Enzyme Manufacturing Facility, Enabling Integrated IVT Supply from R&D to Commercial Scale16 June 2026, 12:30 pm
JUPITER, Fla.--(BUSINESS WIRE)--TriLink, part of Maravai LifeSciences® (NASDAQ: MRVI), today announced the opening of its GMP enzyme manufacturing facility in Jupiter, Florida, designed to help RNA therapeutic developers simplify sourcing and scale production more efficiently. The facility supports a coordinated supply of key RNA manufacturing and IVT workflow materials from early research through commercial production. The launch addresses a long-standing pain point for RNA therapeutics develo
- Catalent Launches Qai™ to Reimagine Quality Assurance for its Manufacturing Services16 June 2026, 12:00 pm
TAMPA, Fla.--(BUSINESS WIRE)--Catalent announces the launch of Qai, an enterprise AI tool designed to elevate the best quality systems and processes across Catalent’s network.
- NeoGenomics Announces Proposed Offering of $275 Million Convertible Senior Notes15 June 2026, 9:24 pm
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics Announces Proposed Offering of $275 Million Convertible Senior Notes
- SurGenTec® Receives FDA Clearance for ION-L™, a Novel Lumbar Facet Fixation System Representing a Paradigm Shift in Minimally Invasive Spine Surgery15 June 2026, 4:00 pm
BOCA RATON, Fla.--(BUSINESS WIRE)-- #FDAClearance--SurGenTec®, a medical device company focused on advancing treatment options for orthopedic and spine surgery, today announced FDA clearance of its ION-L™ Lumbar Facet Fixation System. ION-L™, part of SurGenTec's facet fixation platform, is indicated for the treatment of patients with degenerative disc disease (DDD) from L3 to S1 in skeletally mature patients who have failed conservative care. This clearance is supported by compelling long-term clinical evidenc
- Klick Labs Announces Vocal Biomarker Research Collaboration15 June 2026, 12:29 pm
TORONTO & NEW YORK--(BUSINESS WIRE)-- #AppliedSciences--Researchers at Klick Labs are launching a series of clinical studies with Mayo Clinic in Florida exploring the use of novel vocal biomarkers.
- Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida15 June 2026, 10:00 am
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare’s leading, most comprehensive innovation powerhouse, today announced an investment of more than $1 billion in Jacksonville, Florida to strengthen its Vision operations by scaling U.S.-based manufacturing, packaging and distribution capabilities. The investment includes construction of a new, state-of-the-art distribution facility, alongside advanced manufacturing and packaging technologies to exp
- Walgreens Helps FIFA World Cup™ Fans in Miami Stay Game-Ready with Pharmacy Care and Everyday Essentials11 June 2026, 4:00 pm
DEERFIELD, Ill.--(BUSINESS WIRE)--As millions of fans travel to FIFA World Cup 2026™ matches in the U.S. this summer, Walgreens is making it easier to stay prepared, energized and healthy with convenient access to game-day essentials and trusted pharmacy services. Whether heading to the stadium or wrapping up a late match, Walgreens offers fans in Miami a one-stop destination for official licensed products of the FIFA World Cup 26™ and necessities like water, snacks, sunscreen, over-the-counter
- Paysafe and Skrill Get on Board With Woody & Kleiny’s Outrageous US Soccer Road Trip: 39 Days, 15,000 Miles, Streamed Live 24/711 June 2026, 1:00 pm
JACKSONVILLE, Fla.--(BUSINESS WIRE)--Paysafe (NYSE: PSFE), a global payments platform, is taking its technology to the heart of America’s biggest soccer summer, fueling a 39-day, 15,000-mile streamed road trip powered by viral creators Woody & Kleiny. Known as the ‘In A State’ tour, this record-breaking journey streams live on Kick and TikTok from June 11, as Woody & Kleiny tear through major cities including Los Angeles, Arlington, Boston and East Rutherford, engaging soccer fans and s
- ERMA Systems Named to MM+M's 2026 Agency Partners Power List for AI Health Platforms11 June 2026, 12:00 pm
MIAMI--(BUSINESS WIRE)--ERMA Systems, the AI-powered Medical, Legal, and Regulatory (MLR) review platform built specifically for life sciences organizations, today announced its inclusion on the 2026 Agency Partners Power List published by MM+M, one of the healthcare industry's leading publications. The recognition highlights organizations shaping the future of healthcare commercialization and innovation. ERMA was recognized in the AI Health Platforms category for its transformative approach to
- Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients11 June 2026, 11:45 am
JACKSONVILLE, Fla.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) is expanding the U.S. roll-out of its latest advancement in presbyopia-correcting intraocular lenses (PC-IOLs). TECNIS PureSee IOL is an extended depth of focus (EDOF) lens designed to support visual clarity and quality for patients undergoing cataract surgery.3 Benefits of TECNIS PureSee IOL: Range of vision: Excellent distance and intermediate vision with some near vision3* Low level of bothersome visual symptoms: 97% of p
- DermaSensor Announces Class IIb CE Mark and Collaboration with NHS, Marking the Beginning of Its Global Expansion10 June 2026, 12:00 pm
MIAMI--(BUSINESS WIRE)--DermaSensor, a health technology company transforming skin cancer detection with AI-powered technology, today announced it has received Class IIb CE Mark for the DermaSensor device, enabling commercialization across the European Economic Area (EEA) and marking the beginning of the company’s global expansion strategy. The CE Mark demonstrates that DermaSensor meets European Union standards for safety, health, and environmental protection and paves the way for broader inte
- Summit Therapeutics Announces Proposed Public Offering of Common Stock9 June 2026, 8:47 pm
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (Nasdaq: SMMT) (“Summit,” “we,” or the “Company”) today announced that it has commenced an underwritten public offering of $500.0 million of shares of its common stock. All of the shares in the proposed offering are being offered by Summit. In addition, Summit intends to grant the underwriters a 30-day option to purchase up to an additional $75.0 million of shares of its common stock at the public offering price, less underwriting discounts and c
- OpenEvidence and the American Academy of Ophthalmology Partner to Close the Gap Between Evidence and Eye Care9 June 2026, 4:00 pm
MIAMI & SAN FRANCISCO--(BUSINESS WIRE)-- #ClinicalAI--The American Academy of Ophthalmology, the world’s largest association of eye physicians and surgeons, and OpenEvidence, the most widely used medical AI platform among U.S. physicians, today announced a strategic partnership to integrate the Academy’s Preferred Practice Patterns® and Ophthalmic Technology Assessments directly into the OpenEvidence platform. The partnership makes the Academy’s authoritative ophthalmology guidance available alongside the br
- Shields Health Solutions Brings Integrated Specialty Pharmacy Services to Baptist Health in Jacksonville9 June 2026, 12:00 pm
STOUGHTON, Mass. & JACKSONVILLE, Fla.--(BUSINESS WIRE)--Shields Health Solutions Brings Integrated Specialty Pharmacy Services to Baptist Health in Jacksonville
- Alesis LLC Adds Three New Joint Ventures in a Single Week, Expanding the Alesis Apnea Network to Chicago, Upper Michigan, and South Florida8 June 2026, 6:32 pm
COCOA BEACH, Fla.--(BUSINESS WIRE)--Alesis LLC today announced the addition of three new joint venture locations to the Alesis Apnea Network in a single week: the TMJ & Sleep Therapy Centre of Chicago in St. Charles, Illinois; Alpha Omega Dental Center in Marquette, Michigan; and South Florida Food Allergy Center in Boca Raton, Florida. Together, the additions bring the Alesis Apnea Network to a total of five joint venture locations across five states, connecting patients who suffer from ob
- Republic Bank Brings Community Together for Sixth Annual Juneteenth Celebration8 June 2026, 4:00 pm
LOUISVILLE, Ky.--(BUSINESS WIRE)--This past Saturday, Republic Bank & Trust Company (“Republic” or the “Bank”) hosted its sixth annual Juneteenth celebration at the Republic Bank Foundation YMCA, bringing together community members for a day centered on wellness, education, and culture. The event created a vibrant, welcoming atmosphere where attendees danced, explored local vendor booths, and enjoyed food from businesses proudly operated by Black and women entrepreneurs. “At Republic Bank,
- Xenix Medical Announces FDA Clearance and Full Commercial Launch of the Lux™ Expandable Lumbar Interbody Fusion System8 June 2026, 2:30 pm
ORLANDO, Fla.--(BUSINESS WIRE)-- #InterbodyFusion--Xenix Medical Announces FDA Clearance and Full Commercial Launch of Its Lux Expandable Interbody Fusion System
- Summit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference4 June 2026, 8:30 pm
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it will participate in and present at the 47th Annual Goldman Sachs Global Healthcare Conference in Miami, Florida on Monday, June 8, 2026. Members of the Summit management team will participate in a fireside chat presentation at 10:00 AM ET, providing a corporate overview and update on recent progress, including the development of its innovative investigational bispecific antibody, ivonescimab. The presentatio
- Vycellix to Provide Universal Cell Cancer Therapy Progress Reports at Upcoming Investor & Partnering Meetings4 June 2026, 6:15 pm
BOCA RATON, Fla. & STOCKHOLM--(BUSINESS WIRE)-- #DrivenbyPurpose--Vycellix to attend key upcoming investor & partnering events to share progress reports for its allogeneic cancer cell therapy platforms and products.
- Kalogon Raises $5.75M to Make Sitting Healthier for All4 June 2026, 1:00 pm
MELBOURNE, Fla.--(BUSINESS WIRE)--Kalogon raises $5.75M led by Enable Ventures to expand smart seating solutions for wheelchair users, aviation and beyond.
- Humata Health Joins CMS Electronic Prior Authorization Acceleration Initiative to Speed Care for Patients and Providers4 June 2026, 1:00 pm
WINTER PARK, Fla.--(BUSINESS WIRE)--Humata Health, the leader in AI-powered medical review technology, today announced it has joined the Centers for Medicare and Medicaid Services (CMS) Electronic Prior Authorization Acceleration initiative as a Friend of the Ecosystem. Launched through the CMS Health Tech Ecosystem, it brings together health systems, payers, electronic health record developers, and technology partners to address the workflow, technical, and operational challenges slowing adopt
- GE HealthCare receives FDA 510(k) clearance for MIM Contour ProtégéAI+ 2.0, advancing AI-enabled radiation therapy planning with expanded clinical capabilities4 June 2026, 12:00 pm
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for MIM Contour ProtégéAI+™ 2.0, an AI-enabled auto-contouring software to assist radiation oncology care teams with treatment planning. This can help clinicians reduce treatment planning time, enabling them to focus on delivering more timely and personalized care for patients. The FDA clearance includes a Predetermined Change Control
- Lundbeck Presents New VYEPTI® (eptinezumab-jjmr) and Bocunebart Migraine Data at the American Headache Society 68th Annual Scientific Meeting4 June 2026, 12:00 pm
DEERFIELD, Ill.--(BUSINESS WIRE)--Lundbeck Presents New VYEPTI® (eptinezumab-jjmr) and Bocunebart Migraine Data at the American Headache Society 68th Annual Scientific Meeting
- Kallyope Presents New Data on Novel TRPM8 Channel Blocker Elismetrep for the Acute Treatment for Migraine at the American Headache Society 68th Annual Scientific Meeting4 June 2026, 11:00 am
NEW YORK--(BUSINESS WIRE)--Kallyope is a late-stage biotechnology company focused on developing innovative migraine and metabolic disease therapies for health challenges faced by hundreds of millions of people globally. Today, the Company presented results from several clinical and preclinical studies that support the initiation of Phase 3 studies of elismetrep, a novel TRPM8 channel blocker. Elismetrep is a potentially new approach for migraine and the only agent known to be in late-stage deve
- Pediatrix Medical Group Announces Publication of New Research Addressing Urgent Questions in Neonatology3 June 2026, 8:30 pm
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Pediatrix Medical Group Announces Publication of New Research Addressing Urgent Questions in Neonatology
- Massive Bio and Optellum Collaborate to Accelerate Clinical Trial Access for Early-Stage Non-Small Cell Lung Cancer Patients3 June 2026, 2:01 pm
BOCA RATON, Fla.--(BUSINESS WIRE)--Massive Bio, a global leader in AI-driven precision oncology and clinical trial matching operating across 17+ countries, and Optellum, the leader in AI-enabled lung cancer diagnosis and the developer of the world’s first FDA-cleared clinical decision support software for early-stage lung cancer, today announced a collaboration to bridge early lung cancer detection with clinical trial access for patients with non-small cell lung cancer (NSCLC). The collaboratio
- HSS Chief of Sports Medicine, Riley J. Williams III, MD, Named FIFA Venue Medical Officer for the 2026 World Cup3 June 2026, 2:00 pm
NEW YORK--(BUSINESS WIRE)--FIFA World Cup 26™ has named Hospital for Special Surgery (HSS), ranked No. 1 in orthopedics nationally by U.S. News & World Report (2024–2025), Sports Medicine Surgeon, Riley J. Williams III, MD, as Venue Medical Officer (VMO) for the 2026 World Cup. The New York / New Jersey area will host matches, including the final, taking place in East Rutherford, New Jersey at MetLife Stadium. In this role, Dr. Williams, Chief of the HSS Sports Medicine Institute, Medical D
- STARLIMS Appoints Max Schultz as Chief Executive Officer3 June 2026, 1:36 pm
HOLLYWOOD, Fla.--(BUSINESS WIRE)--STARLIMS, a global leader in enterprise laboratory informatics software, today announced the appointment of Max Schultz as Chief Executive Officer. This leadership transition comes at a time of growth for STARLIMS, with the company accelerating product innovation, expanding its portfolio through strategic acquisitions, and delivering agentic capabilities for enterprise laboratories. As a seasoned enterprise software executive, Schultz brings a strong track reco
- Quanterix To Participate in the Goldman Sachs 47th Annual Global Healthcare Conference3 June 2026, 12:01 pm
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that senior management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference being held in Miami, FL from June 8-10, 2026. Chief Executive Officer Everett Cunningham will engage in a fireside chat at 1:20 pm ET on Tuesday, June 9, during which he will provide an update on the Com
- Omnicell to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 20262 June 2026, 8:01 pm
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026
- Xenix Medical Announces FDA Clearance and Full Commercial Launch of the Riva Posterior Fixation System®2 June 2026, 5:22 pm
ORLANDO, Fla.--(BUSINESS WIRE)-- #MedicalDevices--Xenix Medical announces FDA clearance and full commercial launch for its Riva Posterior Fixation System.
- eternalHealth, Zynix AI, and nirvanaHealth Announce Integrated Partnership to Scale AI-Enabled Care Management and Member Engagement2 June 2026, 2:00 pm
BOSTON & TAMPA, Fla.--(BUSINESS WIRE)--eternalHealth, a Medicare Advantage plan serving Medicare beneficiaries in Massachusetts and Arizona, today announced an integrated partnership with Zynix AI, a healthcare AI platform built to operationalize care management, patient engagement, and quality improvement at scale, and nirvanaHealth, a cloud-native enterprise platform supporting pharmacy benefit management, claims adjudication, and centralized healthcare data infrastructure. Since January 1, 2
- Neuropacs Announces the Publication of a New Study Comparing the First‑of‑Its‑Kind FDA De Novo–Classified Imaging Biomarker for Parkinson’s Disease with CSF Alpha‑Synuclein Seed Amplification Assay2 June 2026, 11:00 am
GAINESVILLE, Fla.--(BUSINESS WIRE)--Neuropacs™ Corp., a leader in AI‑powered neurodiagnostics, today announced the publication of a seminal study co-authored by David Vaillancourt, PhD, the company’s Co‑Founder and Chief Scientific Officer. The research published in Annals of Neurology reveals a positive alpha-synuclein (α-synuclein) seed amplification assay (SAA) and the automated imaging differentiation for parkinsonism (AIDP) provide unique information key to understanding Parkinson’s diseas
- Sarepta Therapeutics to Participate in Upcoming Investor Conferences1 June 2026, 8:30 pm
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in the following investor conferences in June: Goldman Sachs 47th Annual Global Healthcare Conference Fireside chat: Monday, June 8, at 10:40 a.m. ET at the Loews Miami Beach Hotel in Miami Beach, Fla. Oppenheimer CNS and Neuro-Muscular Summit Investor meetings: Wednesday, June 10, 2026 at The Bath Club i
- Align Technology Awards Funding to Universities Worldwide for Advancing Orthodontic and Dental Research1 June 2026, 8:00 pm
TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced the award of twelve research grants to universities under the company’s fifteenth Annual Research Award Program. “Research and clinical evidence continue to be at the core of
- Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China31 May 2026, 1:06 pm
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced positive overall survival (OS) results from the Phase III HARMONi-6 trial, conducted in China and sponsored by Summit’s partner Akeso, Inc. (HKEX Code: 9926.HK), will be presented today as part of the Plenary Session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The presentation is entitled “Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untrea
- Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 202630 May 2026, 12:00 pm
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today presented new results from the AK112-206 trial (NCT05382442), a global, open-label, multicenter Phase II study in first-line metastatic colorectal cancer (mCRC) co-sponsored by Summit and Akeso, featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab. The data were presented today at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The presentation, entitle
- AHF: Florida Lawmakers Reverse HIV Drug Cuts, Restoring Coverage for Thousands29 May 2026, 6:30 pm
TALLAHASSEE, Fla.--(BUSINESS WIRE)--Thousands of Floridians living with HIV will keep the medication that keeps them alive, after the Florida Legislature today passed a state budget that reverses this year's cuts to the AIDS Drug Assistance Program (ADAP). The budget returns eligibility to 400 percent of the federal poverty level, brings back the medications the Department of Health had dropped, including Biktarvy, funds the program with $75 million, and adds independent oversight. "This is wha
- SurGenTec Secures FDA Clearance for ION-C™ - Now Navigation Compatible29 May 2026, 4:00 pm
BOCA RATON, Fla.--(BUSINESS WIRE)-- #CervicalSpine--SurGenTec, LLC, a leader in innovative spine and orthopedic technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) SurGenTec, LLC, a leader in innovative spine and orthopedic technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its ION-C™ navigation instruments for use with the ION-C™ posterior cervical facet fixation implant. The system is engineered for comp
- Massive Bio Partners with TOUCH, The Black Breast Cancer Alliance and Navigating Trials to Expand Cancer Patients' Access to Clinical Trials29 May 2026, 2:14 pm
BOCA RATON, Fla.--(BUSINESS WIRE)--Massive Bio, a global precision oncology company, today announced a new partnership with TOUCH, The Black Breast Cancer Alliance (TOUCH BBCA), a breast cancer patient advocacy organization, and Navigating Trials, a clinical trial navigation platform serving patients across all cancer types. Through this collaboration, Massive Bio's AI-powered trial matching will be made available directly within both organizations' digital platforms, giving their patient commu
- Veradermics to Present at Upcoming June Investor Conferences28 May 2026, 8:30 pm
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that company management will participate in the following upcoming investor conferences in June: Jefferies Global Healthcare Conference on Wednesday, June 3 in New York, NY Reid Waldman, M.D., Chief Executive Officer of Veradermics, and Mark Neumann, Chief Commercial
- Stoke Therapeutics to Present at Upcoming Investor Conferences in June28 May 2026, 8:01 pm
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the following upcoming investo
- Tallahassee Memorial HealthCare and Inspirity Health Partners Launch Strategic Supply Chain Partnership28 May 2026, 1:00 pm
ROCHESTER, Minn.--(BUSINESS WIRE)--Inspirity Health Partners (IHP) has entered into a strategic, multi-year agreement with Tallahassee Memorial HealthCare (TMH) to advance and integrate TMH’s supply chain capabilities through a collaborative, high-performance partnership model. With a well-established category management structure, disciplined operational processes and strong clinical engagement, TMH joins Inspirity from a position of strength. Through this new collaboration, TMH will expand it
- Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences28 May 2026, 11:00 am
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference in New York and Miami, respectively. Gaurav Shah, M.D., Chief Executive Officer, will take part in a fireside ch
- Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 202627 May 2026, 8:05 pm
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced plans to participate in the upcoming Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach, FL. Pulse Biosciences’ Management is scheduled to present on Wednesday, June 10, at 10:00 am ET. A live and recorded webcast of the fireside chat will be available on the “Events Calendar and Presentat
- Alesis LLC Expands to the Pacific Northwest With Dr. Lyly Fisher — First Seattle-Area Provider of Alesis OSA1™27 May 2026, 6:41 pm
COCOA BEACH, Fla. & SEATTLE--(BUSINESS WIRE)--Alesis LLC, the U.S. distributor of the Alesis OSA1™ medical device, today announced a joint venture partnership with Dr. Lyly Fisher, DDS, Diplomate, ABDSM, ASBA -- a dual board-certified sleep dentist with offices in Seattle and Renton, Washington. Dr. Fisher is the first sleep dentist in the Seattle area to offer Alesis OSA1, a breakthrough non-surgical treatment for patients with obstructive sleep apnea (OSA) who cannot tolerate CPAP therapy. Th
- OpenEvidence Integrates ASCO Guidelines, Figures and Flowcharts into Specialty Oncology Model27 May 2026, 4:00 pm
MIAMI--(BUSINESS WIRE)-- #ASCO--Today, OpenEvidence, the most widely used medical knowledge platform, announced an integration of ASCO Guidelines, figures, and flowcharts into the OpenEvidence model. As a part of OpenEvidence's commitment to creating advanced AI models for medical specialties, the company has extended their oncology model to include the ASCO Guidelines. ASCO Guidelines will now appear within OpenEvidence answers, accompanied by peer-reviewed evidence, precise citations, and a direct li
- Groundbreaking Headache Medicine Research on New Frontiers in Treatment, Biomarkers, and the Gut-Brain Axis to be Presented at the American Headache Society® 68th Annual Scientific Meeting27 May 2026, 2:41 pm
MOUNT ROYAL, N.J.--(BUSINESS WIRE)-- #AHSAM--Leading researchers and clinicians gather June 4–7 for the AHS 68th Annual Scientific Meeting, the premier scientific conference in headache medicine.
- Humana completes $83 million Florida infrastructure investment to deepen coordinated patient care approach27 May 2026, 12:00 pm
ORLANDO, Fla.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM), one of the nation’s leading health and well-being companies, today announced the start of full operations of its newest CenterWell Pharmacy® mail order distribution center, in Orlando, Florida. The $83 million, state-of-the-art facility bolsters capacity for prescription medication delivery across Florida and the country and reinforces Humana’s longstanding commitment to providing members and patients across the Sunshine State with a simp
- Arima Genomics Announces Presentation of New Data at ASCO 2026 Supporting Clinical Utility of Hi-C Sequencing in Non-Small Cell Lung Cancer27 May 2026, 12:00 pm
CARLSBAD, Calif.--(BUSINESS WIRE)--Arima Genomics, Inc., a cancer diagnostics company bringing DNA sequence and structure together to advance cancer therapy selection, today announced that it will present new data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29-June 2 in Chicago. The findings in the poster presentation demonstrate the value of Arima’s Hi-C sequencing-based approach to fusion and rearrangement detection, available clinically through t
- NationsBenefits Selected by Sam’s Club to Lead National Expansion of Modern Hearing Centers27 May 2026, 11:00 am
PLANTATION, Fla.--(BUSINESS WIRE)-- #NationsBenefits--NationsBenefits®, the leading healthcare fintech and outcomes platform, today announces its selection by Sam’s Club to manage all Sam’s Club hearing centers across the U.S. This collaboration integrates world-class technology and clinical expertise from NationsHearing® directly into the club to deliver advanced hearing care and outcomes-focused wellness care. These services are designed to improve overall well-being through a modern, member-centric experience
- Viridian Therapeutics to Participate in Upcoming June Investor Conferences27 May 2026, 11:00 am
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that members of its management team will participate in the following upcoming investor conferences: Jefferies Global Healthcare Conference: Fireside chat on Wednesday, June 3, 2026, at 5:30pm ET in New York, NY Goldman Sachs 47th Annual Global Healthcare
- GeneDx to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference26 May 2026, 8:05 pm
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today announced that management will participate in the Goldman Sachs Healthcare Conference from June 8-10 in Miami, FL.
- Arcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference26 May 2026, 8:05 pm
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and autoimmune diseases, announced that its management team will participate in a fireside chat at the upcoming Goldman Sachs Global Healthcare Conference in Miami Beach, FL. The fireside chat will take place on Tuesday, June 9th, 2026, at 10:40am ET. A live webcast o
- Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference26 May 2026, 12:00 pm
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
- NeoGenomics to Present New Research at ASCO Annual Meeting 202626 May 2026, 11:05 am
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will showcase nine scientific abstracts at the 2026 ASCO Annual Meeting, May 29–June 2, 2026, in Chicago (booth #32130).
- Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting26 May 2026, 11:00 am
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced plans to present clinical and real-world data related to the company’s psychiatry and orexin portfolios at the American Society of Clinical Psychopharmacology Annual Meeting, taking place May 26-29, 2026 in Miami. The poster presentations include data related to Alkermes’ proprietary commercial medicines, LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil), and its pipeline of investigational orexin 2 r
- OpenEvidence Launches Voice Mode: The First Native Speech-to-Speech Medical AI21 May 2026, 4:00 pm
MIAMI--(BUSINESS WIRE)-- #clinicalai--OpenEvidence, the most widely used medical AI platform among U.S. physicians, today launched Voice Mode, the first native speech-to-speech medical AI interface. With Voice Mode, OpenEvidence becomes the first multimodal medical AI offering a hands-free way for clinicians to ask questions aloud, and hear cited answers read back, on the same peer-reviewed evidence base. The feature is live in the OpenEvidence web and mobile apps and is free for all users. Physicians reach
- Massive Bio and BeeKeeperAI Deploy Federated Confidential Computing to Expand Oncology Trial Access Across Atlanta’s Underserved Communities21 May 2026, 2:15 pm
BOCA RATON, Fla.--(BUSINESS WIRE)--Massive Bio, a leader in AI-enabled patient recruitment and oncology solutions, today announced expanded access to oncology clinical trials through AI-powered patient pre-screening leveraging a privacy-preserving clinical data collaboration infrastructure. The initiative enables Massive Bio's artificial intelligence-driven clinical trial matching capabilities to operate securely on sensitive cancer data within BeeKeeperAI’s privacy enhancing platform, EscrowAI
- Arrivo Bio to Present Clinical Data on Forvisirvat at 2026 ASCP Annual Meeting21 May 2026, 1:00 pm
MORRISVILLE, N.C.--(BUSINESS WIRE)--Arrivo Bio will be giving both an oral and poster presentation at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, taking place May 26–29 in Miami, Florida. The presentations will highlight Forvisirvat (SP-624), Arrivo’s first-in-class oral activator of the SIRT6 enzyme, currently in a Phase 2b/3 study for major depressive disorder, with data read out expected later this year. Prior Phase 2 data demonstrated a signal of efficacy
- QAD | Redzone Releases New CFO Guide to AI in Manufacturing, Challenging Industry to Focus on Financial Outcomes Over AI Hype21 May 2026, 12:00 pm
MIAMI--(BUSINESS WIRE)--QAD | Redzone, the company delivering the leading manufacturing platform, powered by Agentic AI that executes work and decisions across the business, from the shop floor to the top floor, announced the release of A CFO’s Pragmatic Guide to AI in Mid-Market Manufacturing, a new executive white paper designed to help manufacturing leaders navigate the growing wave of AI investment with greater operational and financial discipline. The paper argues that while AI activity ac
- Ontada Integrates Florida Cancer Specialists & Research Institute Data to Enrich Its Data Ecosystem21 May 2026, 12:00 pm
BOSTON--(BUSINESS WIRE)--Ontada®, a business for oncology insights, announced the inclusion of Florida Cancer Specialists & Research Institute's data into its ecosystem.
- CAN Community Health Launches Healx Solutions to Expand Access in Specialty Therapy Services21 May 2026, 12:00 pm
TAMPA, Fla.--(BUSINESS WIRE)-- #340b--CAN Community Health, the nation’s leading resource in comprehensive health services, today announced a new business entity dedicated to helping health systems, hospitals, physician practices, and specialty clinics unlock the full potential of high-cost specialty therapies while improving patient access, operational efficiency, and long-term sustainability. Healx Solutions launches to support healthcare organizations navigating the growing complexity of specialty m
- Bausch + Lomb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference21 May 2026, 11:15 am
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders and Chief Medical Officer and Head of Research and Development Yehia Hashad, MD, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami, FL, on Tuesday, June 9, 2026, at 1:20 p.m. ET. A live webcast of the session will be av
- Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences21 May 2026, 11:00 am
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the presentation of accepted research at key scientific conferences this spring related to its psychiatry products—LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil)—and its ongoing involvement in sleep medicine. The data presented reflect Alkermes’ ongoing commitment to contributing to the advancement of patient care and expanding the body of evidence in neuroscience. The meetings included: The Psych
- CareDx to Participate in Upcoming Investor Conferences20 May 2026, 8:01 pm
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the company will participate in the following investor conferences: Jefferies 2026 Global Healthcare Conference at the Marriot Marquis in New York, NY. Presentation on Wednesday, June 3, 2026,
- ReCode Therapeutics Achieves a First: Proof of Activity in Primary Ciliary Dyskinesia Patients20 May 2026, 8:00 pm
MENLO PARK, Calif.--(BUSINESS WIRE)--ReCode Therapeutics, a clinical-stage genetic medicines company using lipid nanoparticle delivery to power the next wave of mRNA and gene correction therapeutics, today announced the presentation of clinical data from its RCT1100 PCD inhaled mRNA program at the American Thoracic Society (ATS) 2026 International Conference, held May 15-20, 2026, at the Orange County Convention Center in Orlando, FL. The data represent the first clinical evidence of biological
- CONMED Corporation Appoints Celine Martin and Jeff Mirviss to its Board of Directors20 May 2026, 12:30 pm
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced the appointment of Celine Martin and Jeff Mirviss to its Board of Directors (“Board”), effective July 1, 2026. Ms. Martin will serve as a member of the Audit Committee and the Strategy Committee, and Mr. Mirviss will serve as a member of the Compensation Committee and the Corporate Governance and Nominating Committee. In connection with these appointments, CONMED is increasing the size of its Board to include a total
- Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 202620 May 2026, 12:15 pm
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the ATS 2026 International Conference that is taking place May 15-20, 2026, in Orlando, Florida. The poster reported new biomarker data from the double-blind period of the IMPALA-2 Phase 3 clinical trial evaluating molgramostim for the treatment of aPAP. Below is a summary of the poster presented. Poster Board 401: “Rel
- Autobahn Therapeutics Presents New Preclinical Data at ASCP Annual Meeting Demonstrating Elunetirom Drives Robust Bioenergetic and Neuroplastic Improvements in Neuronal Cultures20 May 2026, 12:00 pm
SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, Inc., a biotechnology company developing restorative treatments for people affected by neuropsychiatric disorders, today announced the presentation of new preclinical data for elunetirom (ABX-002), the company’s lead asset currently in Phase 2 clinical development for adjunctive major depressive disorder (MDD) and bipolar depression, at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting taking place in Miami Beach, F
- Starfighters Space, Inc. Files First Quarter 2026 Form 10-Q20 May 2026, 10:00 am
CAPE CANAVERAL, Fla.--(BUSINESS WIRE)--Starfighters Space, Inc. ("Starfighters" or the "Company") (NYSE American: FJET), the innovative aerospace company, owner and operator of the world's largest fleet of commercial supersonic aircraft, is pleased to report its financial results for the first quarter of fiscal 2026 for the period ended March 31, 2026. To review the full financial results, please view the Company’s recent 10-Q filing with the U.S. Securities and Exchange Commission at www.sec.g
- Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)19 May 2026, 6:15 pm
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the ATS 2026 International Conference that is taking place May 15-20, 2026, in Orlando, Florida. The poster reports long-term efficacy and safety data from the first 48 weeks of the ongoing OL treatment period of the IMPALA-2 Phase 3 clinical trial evaluating molgramostim for the treatment of aPAP. IMPALA-2 is the longe
- Sensome Announces Positive First-in-Human Study Results for In Situ Tumor Detection Technology for Lung Cancer19 May 2026, 1:15 pm
PARIS--(BUSINESS WIRE)-- #cancer--Sensome announces positive first-in-human results for its in situ tumor detection technology for lung cancer.
- LivaNova to Present at Goldman Sachs Global Healthcare Conference in June19 May 2026, 12:00 pm
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach, Fla. Vladimir Makatsaria, Chief Executive Officer of LivaNova; Alex Shvartsburg, Chief Financial Officer; and Phil Kowalczyk, Chief Strategy and Corporate Development Officer, will participate in a fireside chat on Mon., June 8, 2026, at 8 a.m. Eastern Daylight Time. The discussion will be
- CCS Unveils New Research at ISPOR 2026: Longitudinal Coaching and Education Sustain CGM Outcomes Beyond Initiation19 May 2026, 11:00 am
ST. PETERSBURG, Fla.--(BUSINESS WIRE)--As healthcare providers and health plans grapple with growing continuous glucose monitoring (CGM) adoption and persistent gaps in diabetes outcomes alongside growing chronic care costs, a new research-driven poster from CCS is challenging the assumption that simply being prescribed a CGM device is enough. While CGM initiation is often associated with early improvements in glycemic control, new research from CCS suggests those improvements are not consisten
- Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)18 May 2026, 6:55 pm
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, sponsored an oral presentation at the ATS 2026 International Conference that is taking place May 15-20, 2026, in Orlando, Florida. The presentation reported new exercise capacity data from the double-blind period of the IMPALA-2 Phase 3 clinical trial evaluating molgramostim for the treatment of aPAP. Below is a summary of the data presented
- Visium Powers the Next Generation of Healthy Buildings in America’s Model City18 May 2026, 4:59 pm
WEST PALM BEACH, Fla.--(BUSINESS WIRE)--As West Palm Beach rapidly emerges as the next model American city, Visium, a leader in Far-UVC environmental control technology, is playing a central role in shaping how modern buildings support health, wellness, and productivity. Headquartered in the heart of CityPlace, Visium is deeply embedded within the transformation led by Related Ross, one of the country’s most influential real estate developers. With over $10 billion committed to Palm Beach Count
- Vast Therapeutics Presents Late-Breaking Phase 1 Data for Inhaled Therapy ALX1 at ATS 202618 May 2026, 3:30 pm
MORRISVILLE, N.C.--(BUSINESS WIRE)--Vast Therapeutics, a clinical-stage life science company developing nitric oxide-based medicines for serious lung diseases, today announced late-breaking Phase 1 data for its inhaled drug candidate ALX1, presented at the American Thoracic Society (ATS) 2026 International Conference in Orlando, Florida. The data demonstrates that ALX1, a first-in-class nitric oxide prodrug designed for targeted delivery to the lungs, was well tolerated without safety concerns
- Entanglement Chief Research Scientist Dr. Fred Glover Ranked #30 Worldwide in Research.com’s 2026 Best Mathematics Scientists List18 May 2026, 3:00 pm
MIAMI--(BUSINESS WIRE)-- #ai--Entanglement, Inc., a next-generation computing and AI company advancing quantum logic, optimization, and artificial intelligence, today announced that its Chief Research Scientist, Dr. Fred Glover, has been ranked #30 worldwide and #22 in the United States in Research.com’s 2026 Best Mathematics Scientists ranking. The fifth annual edition of the ranking evaluates more than 3,500 leading researchers across the mathematical sciences using the discipline-specific D-index,
- Fujifilm Launches the EB-710US, a Novel Next-Generation, Balloon-less Endobronchial Ultrasound (EBUS) Bronchoscope for Pulmonary Care18 May 2026, 12:00 pm
LEXINGTON, Mass.--(BUSINESS WIRE)--FUJIFILM Healthcare Americas Corporation, a leading provider of endoscopic imaging and endosurgical solutions, today announced the launch of the EB-710US Ultrasound Bronchoscope, a novel next-generation endobronchial ultrasound (EBUS) solution designed to streamline workflow and enhance imaging performance for pulmonologists and healthcare systems. The new scope will be demonstrated at booth #1815 at the American Thoracic Society Conference (ATS), May 18-20 in
- Ideagen becomes Games first AI Technology Principal Partner and backs Commonwealth Netball18 May 2026, 12:00 pm
NOTTINGHAM, England--(BUSINESS WIRE)-- #AI--Ideagen, a global software company with its US headquarters in Fort Lauderdale, has been unveiled as the Official AI Technology Principal Partner of Glasgow 2026, Presenting Partner for Netball and an Official Partner for Team Scotland, becoming one of the primary sponsors of the UK’s biggest sporting event this year. Launched in 2009, Ideagen technology sits at the heart of quality, safety and compliance in the world's most regulated and high-compliance in























































































































































































